|
|
|
|
|
|||||||
|
Session 90
Poster Session
Incidence, Prevalence, and Pathogenic Correlates of Insulin Resistance and Lipodystrophy Syndrome 4:30-6:30 pm 4E-F |
to view the poster for an abstract.| 676-T. | Screening for Insulin Resistance in HIV Infection J. Falutz* and R. Gardiner Montreal Gen. Hosp., QC, Canada
| ||
| 677-T. | Diabetes Mellitus in HIV-Infected Individuals J. S. Currier*1, F. Boyd2, H. Kawabata3, C. Dezii3, B. Burtcel3, and S. Hodder3 1Univ. of California, Los Angeles; 2Johns Hopkins Univ. Bloomberg Sch. of Publ. Hlth., Baltimore, MD; and 3Bristol-Myers Squibb, Princeton, NJ
| ||
| 678-T. | Case-Control Study of Diabetes Mellitus in HIV-Infected Patients C. Yoon*1, R. Gulick1, D. Hoover2, C. Vaamonde1, and M. Glesby1 1Weill Med. Coll. of Cornell Univ., New York, NY and 2Rutgers Univ., Piscataway, NJ
| ||
| 679-T. | The Effect of HAART and HCV Infection on the Development of Diabetes Mellitus S. Mehta*1, R. Moore1, D. Thomas1, R. E. Chaisson1, and M. Sulkowski1 1Johns Hopkins Univ., Baltimore, MD
| ||
| 680-T. | Glucose Homeostasis, Serum Lipids, and Abdominal Adipose Tissue Distribution in Protease Inhibitor (PI)-Treated and Naïve HIV-Infected Children A. Bitnun*, E. Sochett, P. Babyn, C. Arneson, S. Holowka, S. Read, and S. King Hosp. for Sick Children, Univ. of Toronto, ON, Canada
| ||
| 681-T. | HAART-Associated Changes in Body Fat Distribution Are Detectable in HIV-Infected Children Even in the Absence of Clinical Evidence of Lipodystrophy A. Viganò*1, D. Bricalli1, N. Sala1, F. Renzetti2, P. Manzoni2, A. Vanzulli3, and P. Brambilla2 1L. Sacco Hosp., Milan; 2HSR, Milan; and 3Ca' Granda Hosp., Milan, Italy
| ||
| 682-T. | Incidence of Lipodystrophy and Glucose and Lipid Abnormalities During the Follow-up of a Cohort of HIV-Infected Patients Started on a Protease Inhibitor (PI)-Containing Regimen M. Saves1, G. Chêne*1, P. Dellamonica2, R. Lassalle1, C. Leport3, J. Capeau4, J. M. Bard5, C. Bazin6, R. Salamon1, and F. Raffi7 for the APROCO (ANRS EP11) Study Group 1INSERM U330, Bordeaux; 2Hosp. L’archet, Nice; 3Hosp. Bichat, Paris; 4INSERM U402, Paris; 5UFR Pharmacie, Nantes; 6Hosp. Côte de Nacre; and 7Hôtel-Dieu, Nantes, France
| ||
| 683-T. | Effect of Nucleoside (NRTI) Intensification on Prevalence of Morphologic Abnormalities (MoAs) at Year 5 of Ritonavir (RTV) plus Saquinavir (SQV) Therapy in an HIV-Infected Cohort C. Cohen*1, Y. Shen2, R. Rode2, D. W. Cameron3, J. Mellors4, C. Farthing5, D. Poretz6, M. Markowitz7, D. Ho7, D. Mcmahon4, D. Drennan8, K. Selness2, E. Sun2, T. Kakuda*2, A. J. Japour2, and J. Ryan2 for the M96-462 Study Group 1Comm. Res. Initiative, Boston, MA; 2Abbott Labs, Abbott Park, IL; 3Univ. of Ottawa and Ottawa Hosp., ON, Canada; 4Univ. of Pittsburgh, PA; 5AIDS Healthcare, Los Angeles, CA; 6Inf. Dis. Physicians, Annandale, VA; 7Aaron Diamond AIDS Res. Ctr., Rockefeller Univ., New York, NY; and 8HIV Inst., Davies Med. Ctr., San Francisco, CA
| ||
| 684-T. | Fat Redistribution in HIV Patients on Non-Protease Inhibitor (PI) Regimens- Study in 6 Centres in Nigeria S. Koko-Ekong*1, U. Azubike1, E. Ekong2, A. Uwah.3, and O. Akinlade2 1Shekomed AIDS/STD Control Organisation (SACO); 2Nigerian Army Reference Hosp., Yaba; and 3Central Publ. Health Lab., Yaba, Lagos, Nigeria
| ||
| 684a-T. | Incidence and Risk Factors for Lipoatrophy (Abnormal Fat Loss) in Ambulatory HIV-1-Infected Patients K. Lichtenstein*1, K. Delaney2, D. Ward3, A. Moorman2, K. Wood4, and S. Holmberg2 1Rose Med. Ctr., Univ. of Colorado Hlth. Sci. Ctr., Denver; 2CDC, Atlanta, GA; 3Dupont Circle Physicians Group, Washington, DC; and 4Cerner Corp., McLean, VA
| ||
| 685-T. | Evolution of Fat Atrophy (FA) and Fat Deposition (FD) over 1 Year in a Cohort of HIV-Infected Men and Women D. L. Jacobson*, T. Knox, S. Gorbach, and C. Wanke Tufts Univ. Sch. of Med., Boston, MA
| ||
| 686-T. | Treatment with Dideoxynucleosides Is Reflected in Lowered Mitochondrial DNA in Subcutaneous Fat C. Cherry*1, M. Gahan1, S. Lewin2, 3, J. McArthur4, and S. Wesselingh1 1Monash Univ., Alfred Hosp., Melbourne, Australia; 2Royal Melbourne Hosp., Australia; 3Univ. of Melbourne, Australia; and 4Johns Hopkins Univ., Baltimore, MD
| ||
| 687-T. | Comparison of Regional Body Composition Changes in Lipodystrophy with Those of Tuberculosis-Related Wasting N. Paton*, Y-M. Ng, Y-K. Chua, J. Aboulhab, and F. Karim Tan Tock Seng Hosp., Singapore
| ||
| 688-T. | Anthropometric Criteria Define Visceral Fat Excess in Patients with HIV-Associated Adipose Redistribution Syndrome (HARS), a Subset of HIV Lipodystrophy D. Kotler1, E. Engelson1, S. Heymsfield1, P. Chang2, N. Muurahainen2, and J. Gertner*2 1St. Lukes-Roosevelt Hosp. Ctr., New York, NY and 2Serono Inc., Norwell MA
| ||
| 689-T. | Differentiating Hypercholesterolemia Associated with Antiretroviral Therapy (ART) S. Mauss*1, J. Stechel2, R. Willers3, G. Schmutz1, and W. Richter4 1Ctr. for HIV and Hepatogastroenterology, Düsseldorf; 2Cologne; 3Computer Ctr., Univ., Düsseldorf; and 4Res. Inst. for Lipid Metabolism, Windach, Germany
| ||
| 690-T. | Step-by-Step Evaluation of the Impact of Different Protease Inhibitors on Adipogenesis: Pathophysiological Insights and Relevance to the Clinic M. Caron*, M. Auclair, M. Kornprobst, and J. Capeau INSERM U.402, Faculté de Med., Saint-Antoine, Paris, France
| ||
| 691-T. | Total Energy Expenditure Is Increased in Men with the HIV Lipodystrophy Syndrome L. Kosmiski*, D. Kuritzkes, T. Sharp, J. Hamilton, K. Lichtenstein, J. Hill, and R. Eckel Univ. of Colorado Hlth. Sci. Ctr., Denver
|
